CSTI571X2103: A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3K) inhibitor BYL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib.
The purpose of this study is to find out if the addition of BYL719 (the study drug), at different dose levels, to imatinib is safe and has beneficial effects in people who failed the GIST therapy with imatinib and sunitinib.
Unresectable or metastatic GIST
* Subjects must have histologically confirmed unresectable or metastatic gastroIntestinal stormal tumor (GIST)
* Subjects must be 18 or older
* Subjects must have failed prior therapy with imatinib followed by sunitinib
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression or unacceptable side effect
Tracy Walker, RN (503) 346-1183 or email@example.com
You may be reimbursed up to $57.00 per study visit for meals and parking fees. In addition, you may be able to receive up to $250.00 for hotel stays per study visit where applicable.